It is known that peripheral infections, accompanied by inflammation, represent significant
risk factors for the development of neurological disorders by modifying brain development or
affecting normal brain aging. The acute effects of systemic inflammation on progressive and persistent
brain damage and cognitive impairment are well documented. Anti-inflammatory therapies may
have beneficial effects on the brain, and the protective properties of a wide range of synthetic and
natural compounds have been extensively explored in recent years. In our previous review, we provided
an extensive analysis of one of the most important and widely-used animal models of peripherally
induced neuroinflammation and neurodegeneration - lipopolysaccharide (LPS)-treated mice.
We addressed the data reproducibility in published research and summarized basic features and data
on the therapeutic potential of various natural products, nutraceuticals, with known antiinflammatory
effects, for reducing neuroinflammation in this model. Here, recent data on the suitability
of the LPS-induced murine neuroinflammation model for preclinical assessment of a large
number of nutraceuticals belonging to different groups of natural products such as flavonoids, terpenes,
non-flavonoid polyphenols, glycosides, heterocyclic compounds, organic acids, organosulfur
compounds and xanthophylls, are summarized. Also, the proposed mechanisms of action of these
molecules are discussed.